Gerresheimer delivers solid results in the financial year 2024 despite market headwinds Organic growth: revenue +2.9%, adjusted EBITDA +4.1% Destocking in vial business partially offset by strong growth in medical devices Growth strategy execution: capacity expansions and higher revenue share from solutions for biologics Bormioli Pharma to boos [ … ]

Gerresheimer AG confirms discussions with private equity investors on potential takeover offer Düsseldorf, February 7, 2025 – The Executive Board of Gerresheimer AG (ISIN: DE000A0LD6E6, "Gerresheimer") reacts to press reports and confirms that Gerresheimer is in early-stage discussions with private equity investors who have expressed, on an infor [ … ]